缺血性心肌病伴ICD患者室速消融:预防性与延迟策略对比(BERLIN VT)
BERLIN VT研究为前瞻性多中心随机试验,纳入左室射血分数30%-50%且记录到室速的稳定缺血性心肌病患者,比较ICD植入前预防性消融与3次ICD电击后延迟消融策略。主要终点为全因死亡及因症状性室性心律失常或心衰加重非计划住院的复合终点,预防组32.9%对延迟组27.7%(HR 1.09,95%CI 0.62-1.92,P=0.77),研究因无效提前终止。预防性消融未减少主要终点事件,但适当ICD治疗比例数值上降低(34.2% vs 47.0%,P=0.020)。
要点
- 预防性VT消融未降低1年死亡或住院复合终点(HR 1.09,P=0.77)
- 预防组适当ICD治疗比例数值更低(34.2% vs 47.0%,P=0.020)
- 研究因预设无效标准提前终止,样本量有限
核心结论
- 在缺血性心肌病伴ICD患者中,ICD植入前预防性VT消融与3次ICD电击后延迟消融相比,未减少1年全因死亡或症状性室性心律失常/心衰加重住院的复合终点。
研究设计与样本
- BERLIN VT为前瞻性、开放、平行随机试验,在26个中心开展。
- 纳入稳定缺血性心肌病、左室射血分数30%-50%且有记录VT的患者,按1:1随机分配至预防性或延迟消融策略。
- 预防性消融组76例,延迟消融组83例,平均随访396±284天。
主要发现
- 主要复合终点在预防组发生25/76(32.9%),延迟组23/83(27.7%),HR 1.09(95%CI 0.62-1.92),P=0.77。
- 预防组与延迟组分别有6例与2例死亡(7.9% vs 2.4%,P=0.18),8例与2例因心衰加重住院(10.4% vs 2.3%,P=0.062)。
- 预防组与延迟组分别有15例与21例因症状性室性心律失常住院(19.5% vs 25.3%,P=0.27)。
- 持续室性快速性心律失常发生率39.7% vs 48.2%(P=0.050),适当ICD治疗34.2% vs 47.0%(P=0.020)。
临床怎么用
- 对于缺血性心肌病伴ICD适应证且记录到VT的患者,ICD植入前预防性消融未显示优于延迟至3次ICD电击后消融。
局限性
- 研究因预设无效标准提前终止,样本量有限,事件数少。
- 随访时间较短(平均约1年)。
- 开放标签设计可能影响住院等主观终点的判定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of VT in patients with implantable cardioverter-defibrillators (ICDs). The appropriate timing of VT ablation and its effects on mortality and heart failure progression remain a matter of debate. In patients with life-threatening arrhythmias necessitating ICD implantation, we compared outcomes of preventive VT ablation (undertaken before ICD implantation to prevent ICD shocks for VT) and deferred ablation after 3 ICD shocks for VT. METHODS: The BERLIN VT study (Preventive Ablation of Ventricular Tachycardia in Patients With Myocardial Infarction) was a prospective, open, parallel, randomized trial performed at 26 centers. Patients with stable ischemic cardiomyopathy, a left ventricular ejection fraction between 30% and 50%, and documented VT were randomly assigned 1:1 to a preventive or deferred ablation strategy. The primary outcome was a composite of all-cause death and unplanned hospitalization for either symptomatic ventricular arrhythmia or worsening heart failure. Secondary outcomes included sustained ventricular tachyarrhythmia and appropriate ICD therapy. We hypothesized that preventive ablation strategy would be superior to deferred ablation strategy in the intention-to-treat population. RESULTS: During a mean follow-up of 396±284 days, the primary end point occurred in 25 (32.9%) of 76 patients in the preventive ablation group and 23 (27.7%) of 83 patients in the deferred ablation group (hazard ratio, 1.09 [95% CI, 0.62-1.92]; P=0.77). On the basis of prespecified criteria for interim analyses, the study was terminated early for futility. In the preventive versus deferred ablation group, 6 versus 2 patients died (7.9% versus 2.4%; P=0.18), 8 versus 2 patients were admitted for worsening heart failure (10.4% versus 2.3%; P=0.062), and 15 versus 21 patients were hospitalized for symptomatic ventricular arrhythmia (19.5% versus 25.3%; P=0.27). Among secondary outcomes, the proportions of patients with sustained ventricular tachyarrhythmia (39.7% versus 48.2%; P=0.050) and appropriate ICD therapy (34.2% versus 47.0%; P=0.020) were numerically reduced in the preventive ablation group. CONCLUSIONS: Preventive VT ablation before ICD implantation did not reduce mortality or hospitalization for arrhythmia or worsening heart failure during 1 year of follow-up compared with the deferred ablation strategy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02501005.
引用
- Willems S, Tilz RR, Steven D, et al. Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial. Circulation. 2020. PMID: 32000514. doi:10.1161/CIRCULATIONAHA.119.043400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。